Stockscreener 앱 받기
23.08
1.91%
-0.43
전일 마감가:
$23.51
열려 있는:
$23.66
하루 거래량:
359.95K
Relative Volume:
0.37
시가총액:
$1.81B
수익:
$399.58M
순이익/손실:
$-54.04M
주가수익비율:
-30.77
EPS:
-0.75
순현금흐름:
$40.13M
1주 성능:
-13.47%
1개월 성능:
-12.62%
6개월 성능:
-47.11%
1년 성능:
-0.52%
1일 변동 폭
$23.03
$23.79
1주일 범위
$22.61
$27.10
52주 변동 폭
$19.73
$47.32
Veracyte Inc Stock (VCYT) Company Profile
명칭
Veracyte Inc
전화
(650) 243-6300
주소
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
VCYT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
23.09 | 2.09B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
407.60 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.28 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
519.59 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.00 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
159.34 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | Craig Hallum | Buy |
| 2024-12-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-16 | 개시 | UBS | Buy |
| 2024-10-10 | 개시 | Guggenheim | Buy |
| 2024-02-23 | 재확인 | Needham | Buy |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-11-18 | 재개 | Goldman | Buy |
| 2021-06-15 | 개시 | Raymond James | Outperform |
| 2021-02-18 | 재개 | Needham | Buy |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-09 | 개시 | Morgan Stanley | Underweight |
| 2019-07-31 | 개시 | Lake Street | Buy |
| 2019-07-02 | 개시 | Needham | Buy |
| 2018-11-29 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Janney | Neutral → Buy |
| 2017-11-07 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-11-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-08-31 | 재개 | BTIG Research | Buy |
| 2016-11-14 | 재개 | Leerink Partners | Outperform |
| 2015-12-18 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-11 | 재확인 | Leerink Partners | Outperform |
| 2013-11-26 | 개시 | William Blair | Outperform |
모두보기
Veracyte Inc 주식(VCYT)의 최신 뉴스
What analysts say about Veracyte Inc. stockUnrivaled growth potential - jammulinksnews.com
What drives Veracyte Inc. stock priceExceptional stock performance - Autocar Professional
Are Veracyte, Inc.'s (NASDAQ:VCYT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? - simplywall.st
Is Veracyte Inc. a good long term investmentHigh-margin investment plays - Autocar Professional
Veracyte Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - jammulinksnews.com
Principal Financial Group Inc. Raises Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
When is the best time to buy Veracyte Inc. stockMinimized Risk Maximum Return - Newser
Will Veracyte Inc. stock split in the near futureBreakout Momentum Stocks - Newser
Veracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025 - Lelezard
Should You Continue to Hold Veracyte Stock in Your Portfolio Now? - Nasdaq
How Veracyte Inc. stock performs during market volatility5x Profit Potential - Newser
Why Veracyte Inc. stock attracts strong analyst attentionReal Chart Play - Newser
What makes Veracyte Inc. stock price move sharplyTop Performer Shortlist - Newser
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Teacher Retirement System of Texas - Defense World
Allspring Global Investments Holdings LLC Purchases 4,792 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - BioSpace
Veracyte's Afirma GRID Studies at ENDO 2025: A Paradigm Shift in Thyroid Cancer Diagnostics and Personalized Medicine - AInvest
Veracyte, Inc. Announces Multiple Afirma Grid Studies Will Be Presented At Endo 2025 - MarketScreener
Veracyte's Afirma GRID: Pioneering Precision Oncology and Driving Sustainable Growth - AInvest
Wealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte Q3 2024 slides: Revenue surges 29%, guidance raised for third time By Investing.com - Investing.com South Africa
Veracyte Q3 2024 slides: Revenue surges 29%, guidance raised for third time - Investing.com Canada
Veracyte's Russell 2000 Growth Index Inclusion: A Catalyst for Liquidity and Institutional Momentum - AInvest
Veracyte, Inc.(NasdaqGM: VCYT) dropped from Russell 2000 Value Index - MarketScreener
Wall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to Hold - Defense World
Veracyte exploring external buyers for divestiture of French unit’s activities - TipRanks
GAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Veracyte shareholders approve 2.5 million share increase to equity plan - Investing.com
Veracyte shareholders approve 2.5 million share increase to equity plan By Investing.com - Investing.com India
Insider Sell: Karin Eastham Sells Shares of Veracyte Inc (VCYT) - GuruFocus
Recent 3.7% Pullback Isn't Enough to Hurt Long-term Veracyte (NASDAQ:VCYT) Shareholders, They're Still up 56% Over 3 Years - 富途牛牛
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business - simplywall.st
Veracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved Profitability - Insider Monkey
Veracyte Inc (VCYT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Veracyte Inc 주식 (VCYT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bhanji Muna | Director |
Jun 13 '25 |
Sale |
26.67 |
4,589 |
122,367 |
29,989 |
1.06%
0.65%
자본화:
|
볼륨(24시간):